1 E: investor @claritypharmaceuticals.com W: www.claritypharmaceuticals.com A C N: 143 005 341 T: +61 (0)2 9209 4037 CLARITY P HARMACEUTICALS LIMITED ASX MEDIA RELEASE 25 November 2021 Results of Annual General Meeting 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to present the results of its Annual General Meeting held earlier today. This announcement has been authorised for release by the Executive Chairman. For more information, please contact: Clarity Pharmaceuticals Dr Alan Taylor Simon Hinsley Executive Chairman Investor/Media Relations ataylor@claritypharm.com simon@nwrcommunications.com.au +61 401 809 653 About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults. www.claritypharmaceuticals.com ANNUAL GENERAL MEETING Thursday, 25 November, 2021 CLARITY PHARMACEUTICALS LIMITED Short Description For Against For Against Abstain ** As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda. Resolution Voted on at the meeting Total votes cast in the poll (where applicable) Abstain Result Discretionary (open votes) No Strike Y/N/NA Proxy Votes (as at proxy close) RESULT OF ANNUAL GENERAL MEETING (ASX REPORT) 67,281,166 686 451,792 1 REMUNERATION REPORT 89,422 686 451,792 62,569,394 0.67% 99.33% Carried 99.14% 0.72% 0.14% N 125,406,029 4,346 105,469 2 RE-ELECTION OF DIRECTOR MS ROSANNE ROBINSON 89,422 4,346 105,469 120,694,257 0.08% 99.92% Carried 99.84% 0.09% 0.07% NA 125,457,048 4,346 54,450 3 APPOINTMENT OF GRANT THORNTON AUDIT PTY LTD AS AUDITOR 79,422 4,346 54,450 120,755,276 0.04% 99.96% Carried 99.89% 0.05% 0.07% NA ** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item Printed: 25/11/2021 11:03:11AM Page 1 of 1 This report was produced from the Link Market Services Meeting System
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Clarity Pharmaceuticals Ltd (ASX:CU6) when you join Listcorp.